Skip to main content
. 2020 Aug 31;8(3):490. doi: 10.3390/vaccines8030490

Figure 5.

Figure 5

PRRSV-A2MC2-P90 vaccination evoked a higher titer of neutralizing antibodies in vaccinated piglets that correlated with reduced virus shedding and viremia. (A). Serum samples from piglets in the PRRSV-A2MC2-P90-vaccinated group (A2P90/HP-PRRSV) or TJM F92-vaccinated group (TJM-92/HP-PRRSV) were collected at indicated dpc after HP-PRRSV challenge. Sera were further tested via neutralizing assays using 2-fold serial dilutions to evaluate virus neutralizing activity against HP-PRRSV infection of MARC-145 cells. Data are expressed as the mean ± SD and were subjected to a Student’s t-test. Significant differences of NAbs titers between A2P90/HP-PRRSV and TJM-92/HP-PRRSV at indicated dpc (except 3 dpc) were marked with * (p < 0.05), or ** (p < 0.01) or NS (not significant). (B). Nasal swabs and serum samples from both vaccination groups collected at 21 dpc were processed using TRIzol reagent and subjected to PRRSV RNA detection using IDEXX RealPCR PRRSV-2 RNA Mix. The Ct value of each sample is presented as the mean ± SD and all data were subjected to a Student’s t-test. Significant differences of Ct values between the A2MC2-P90-vaccinated group (A2P90/HP-PRRSV) and TJM F92-vaccinated group (TJM-92/HP-PRRSV) are marked with * (p < 0.05).